⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2003Breast Cancer ResearchOpen Access

Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma – another point of view

María Victoria Preciado

View Full Paper

Ask AI

Bookmark

Share

Abstract

EBV-encoded small RNA; EBNA-1 = EBV nuclear antigen 1; EBV = Epstein-Barr virus; PCR = polymerase chain reaction.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

María Victoria Preciado (2003) studied this question.

synapsesocial.com/papers/6ab07ae76672688073e9591b https://doi.org/10.1186/bcr599

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Lack of evidence for an association of Epstein–Barr virus infection with breast carcinomaOriginal Research · 2002 · 83 citations
2Detection of Epstein-Barr Virus in Invasive Breast CancersOriginal Research · 1999 · 324 citations
3Frequency and genome load of Epstein–Barr virus in 509 breast cancers from different geographical areas*Original Research · 2001 · 152 citations
4Prognostic value of tumor maximum standardized uptake value on positron emission tomography/computed tomography for 10-year survival in early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: a retrospective studyBreast Cancer Research · Mon,
5Spatial localization of RNAs within the breast tumor microenvironment may affect progression and recurrence of DCISBreast Cancer Research · Fri,

More from Breast Cancer Research

Age at first live birth modifies the association between age at menarche and breast cancer risk in the UK Biobank cohortThu,
Treatment delay and survival in patients with breast cancer by stage and cardiovascular comorbidity: a nationwide Korean cohort studyMon,
Single-cell and spatial profiling of cysteine cathepsins identifies tumor states relevant to antibody-drug conjugates in breast cancerSun,
Overcoming acquired resistance in breast cancer: translational strategies for targeted protein degradation of resistance-driving proteinsWed,
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 studyMon,